Applied Genetic Technologies Corporation
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Susan Washer
- Full Time Employees
- 102
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 14193 Nw 119Th Terrace, Suite #10 Alachua FL United States of America 32615
- IPO Date
- Mar 27, 2014
- CIK
- 0001273636
- Website
- agtc.com
- Similar Companies
- Business
- Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation (AGTC) is a clinical-stage biotechnology company focused on developing proprietary gene therapies for patients with rare and debilitating ophthalmologic, otologic, and central nervous system diseases. The company offers a pipeline of product candidates targeting inherited retinal diseases, including AGTC-501 (laruparetigene zosaparvovec) for X-linked retinitis pigmentosa (XLRP), programs for achromatopsia (ACHM CNGB3 and ACHM CNGA3 mutations), X-linked retinoschisis (XLRS), blue cone monochromacy, wet age-related macular degeneration, and optogenetics-based therapies for advanced retinal disease; it also advances preclinical candidates for alpha-1 antitrypsin deficiency, adrenoleukodystrophy, otology indications such as genetic deafness, and central nervous system disorders including frontotemporal dementia and amyotrophic lateral sclerosis. AGTC leverages expertise in adeno-associated virus (AAV) vector design, synthetic promoters, expression cassettes, and manufacturing to create customized therapies with high unmet medical need, clinical feasibility, and commercial potential, primarily serving patients with orphan genetic diseases through subretinal and intravitreal delivery methods. Founded in 1999 and headquartered in Alachua, Florida, with additional operations in Cambridge, Massachusetts, the company operates in the United States and collaborates with partners like Bionic Sight for optogenetics and Otonomy for neurotology. In a major strategic shift, AGTC was acquired in December 2022 by a Syncona Limited portfolio company through a tender offer valued at approximately $23.5 million upfront plus up to $50 million in contingent value rights, after which its lead asset AGTC-501 and broader pipeline were integrated into Beacon Therapeutics, a new ophthalmic gene therapy entity launched in June 2023 with £96 million ($120 million) in funding from Syncona and others including Oxford Science Enterprises. Beacon Therapeutics, building on AGTC's programs, raised an additional $170 million in Series B financing in 2024 led by Forbion to advance development, and reported positive interim data from Phase 2 DAWN and SKYLINE trials of laru-zova (formerly AGTC-501) in 2025, showing sustained visual function improvements including low luminance visual acuity and microperimetry in XLRP patients; enrollment completed in the pivotal Phase 2/3 VISTA trial with topline data expected in the second half of 2026. These changes reflect AGTC's transition from independent public operations (delisted from Nasdaq post-acquisition) to a supported platform within Beacon's focus on rare and prevalent blinding ocular diseases like XLRP, cone-rod dystrophy, and dry AMD.
Make Money With Penny Stocks in November? 3 Methods to Use
AGTC to Participate in Upcoming Investor Conferences
AGTC to Participate in Upcoming Investor Conferences
AGTC to Present at Upcoming American Society of Retina Specialists Annual Meeting
Aurion Biotech Appoints Dr. Michael Goldstein as President and Chief Medical Officer
AGTC to Participate in Upcoming Investor Conferences
Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q2 2022 Results - Earnings Call Transcript
AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 14, 2022
Applied Genetic Technologies (AGTC) Reports Q1 Loss, Lags Revenue Estimates
AGTC to Present at Upcoming Dry AMD Therapeutic Development Summit
AGTC Announces Two Key Leadership Team Appointments
AGTC to Present at Upcoming Cell & Gene Meeting on the Mesa
AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
Kids Suffer Adverse Reactions In Applied Genetic's Color Blindness Gene Therapy Trial
Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q4 2021 Results - Earnings Call Transcript
AGTC Provides Financial Results for the Fourth Quarter and Year Ended June 30, 2021
AGTC to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
AGTC to Present at the 2021 Wells Fargo Virtual Healthcare Conference
Greater Gift, AGTC, and 2020 On-site Partner To Honor & Celebrate Clinical Trial Participants and Provide Eye Exams to Underserved Children in the Local Community
AGTC Announces Sponsorship of Achroma Corp's No Roadblocks Program